ERBB2 and breast cancer: 31,314 However, after the FDA eventually withdrew the approval of bevacizumab for metastatic HER2 negative breast cancer, 32,315 the EMA did not follow suit immediately because of the increased PFS the drug in combination with capecitabine or paclitaxel showed. 316